Skip to main content

IAVI 005

Phase:
I
Status:
Completed
Strategies:
Viral Vector - Pox; DNA
Candidates:
MVA.HIVA; DNA.HIVA
Countries:
United Kingdom
Volunteers:
9
Partners:
John Warin Ward, The Churchill, Headington, Oxford, UK; Medical Research Council (MRC), Oxford, UK.

 
Study Summary:
 
This is an open-label Phase I study to evaluate the safety and immunogenicity of a prime-boost combination of a clade A HIV-DNA/MVA prime-boost combination in HIV-uninfected healthy volunteers at low risk for HIV infection. On days 0 and 21, participants who previously received a DNA vaccine in the trial IAVI 001 and who volunteer again will be boosted with an intradermal injection of  5 x10^7 pfu of HIV-MVA in the latero-dorsal aspect over the deltoid muscle.